Vascular system & stroke

💊 = pharma ties / conflict of interest

Cohort & case-control studies

Ayele HT, Reynier P, Azoulay L, et al. The cardiovascular safety of 5-alpha-reductase inhibitors among men with benign prostatic hyperplasia: a population-based cohort study. Am J Med. 2023. doi:10.1016/j.amjmed.2023.06.021PubMed

Ayodele O, Cabral HJ, McManus D, Jick S. The risk of venous thromboembolism (VTE) in men with benign prostatic hyperplasia treated with 5-alpha reductase inhibitors (5ARIs). Clin Epidemiol. 2021. doi:10.2147/CLEP.S317019 • PubMed • PMC full text

Chou CH, Lin CL, Lin MC, Sung FC, Kao CH. 5α-reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. J Endocrinol Invest. 2015. doi:10.1007/s40618-015-0263-1PubMed

Skeldon SC, Macdonald EM, Law MR, et al. The cardiovascular safety of dutasteride. J Urol. 2017. doi:10.1016/j.juro.2016.11.082PubMed

💊 [Funded by Yamanouchi Europe] Souverein PC, Herings RM, Man in ‘t Veld AJ, de la Rosette JJ, Farmer RD, Leufkens HG. Study of the association between ischemic heart disease and use of alpha-blockers and finasteride indicated for the treatment of benign prostatic hyperplasia. Eur Urol. 2002. doi:10.1016/s0302-2838(02)00273-7PubMed

💊 [See COI disclosures] Zhang J, Latour CD, Olawore O, et al. Cardiovascular outcomes of α-blockers vs 5-α reductase inhibitors for benign prostatic hyperplasia. JAMA Netw Open. 2023. doi:10.1001/jamanetworkopen.2023.43299 • PubMed • PMC full text

Review

Traish AM, Guay AT, Zitzmann M. 5α-reductase inhibitors alter steroid metabolism and may contribute to insulin resistance, diabetes, metabolic syndrome and vascular disease: a medical hypothesis. Horm Mol Biol Clin Investig. 2014. doi:10.1515/hmbci-2014-0025 • PubMed

Systematic review & meta-analysis

Loke YK, Ho R, Smith M, et al. Systematic review evaluating cardiovascular events of the 5-alpha reductase inhibitor – dutasteride. J Clin Pharm Ther. 2013. doi:10.1111/jcpt.12080 • PubMed

Case reports

Choi BK, Cheon K, Cho BH, Jung JW, Lee KY. Cerebral venous sinus thrombosis associated with dutasteride use. Yonsei Med J. 2020. doi:10.3349/ymj.2020.61.6.553 • PubMed • PMC full text

Gaddameedi SR, Khan MA, Arty F, et al. An unusual case of thalamic stroke in a young adult with patent foramen ovale and finasteride use. Cureus. 2024. doi:10.7759/cureus.60300 • PubMedPMC full text

Kang DW, Jeong HG, Kim HR, et al. Finasteride induced cerebral venous thrombosisJournal of the Korean Neurological Association. 2015;33(3):238-240. PDF at ResearchGate

Kuno T, Uchida Y, Usami T, et al. A young male of [sic] hemorrhagic cerebral infarction associated with finasteride and minoxidil. Nosotchu. 2020;42(4):244-247. Japanese. doi:10.3995/jstroke.10722 • ResearchGate • Automated translation to English (unofficial)

Lear JT, Byrne JP. Finasteride-related cutaneous vasculitis. Postgraduate Medical Journal. 1996. doi:10.1136/pgmj.72.844.127-a • PubMedPMC full text

Prajapati J, et al. Finasteride-induced CVST: rare drug to cause CVT used for alopecia. J Stroke Med. 2019 Jun;2(1):62-63. doi:10.1177/2516608519860317

Tsuji Y, Nakayama T, Bono K, Kitamura M, Imafuku I. [Two cases of stroke associated with the use of finasteride, an approved drug for male-pattern hair loss in Japan]. Rinsho Shinkeigaku. 2014;54(5):423-8. Japanese. doi:10.5692/clinicalneurol.54.423 • PubMed